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Abstract 
e-Mental Health is an emerging area of research that has the potential to overcome some of 
the current barriers to progress in working with people at Clinical High Risk for Psychosis 
(CHR-P). This article provides an overview of how e-Mental Health could be utilised in the 
detection, prediction and treatment in the CHR-P population. Specifically, we evaluate e-
detection, e-prediction and e-therapeutics for this clinical population. e-Mental Health holds 
great promise to improve current management of CHR-P individuals. 
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INTRODUCTION 
The identification of people at Clinical High Risk for Psychosis (CHR-P) [1] offers a unique 
opportunity to alter the illness course of psychotic disorders [2]. These individuals, often 
have several risk factors for psychosis [3] and typically present with attenuated psychotic 
symptoms in the context of a recent decline in functioning [4]. They display symptoms and 
functional impairments that are qualitatively similar to those observed in established mental 
disorders [5]. The risk of transition to psychosis within two years in these individuals is 
approximately 20% [6]. This risk is not the same across the different CHR-P subgroups. In 
particular, individuals meeting criteria for short-lived psychotic episode show a distinctive 
and very high risk of developing persistent psychotic disorders, which cumulates to about 
50% at two years [7]. CHR-P individuals presenting with a short-lived psychotic episode 
which is spontaneously remitting but characterised by disorganised behaviour have an even 
higher risk of developing a persistent psychotic disorder, cumulating at 89% at five years [8].  
These individuals also have unmet clinical needs that are not typically addressed by the 
current configuration of mental health services [9,10]. Overall, the risk for the development 
of psychosis from a CHR-P stage has declined from 29% [11] to 20% [6] in recent years, 
though not across all sites [12]. This variable transition risk is due to different sampling 
strategies being adopted to recruit these individuals [13]. Emerging evidence indicates that 
the method of recruitment prior to a CHR-P assessment is fundamental in enriching their 
actual level of risk for psychosis [13]. 
 
Although the CHR-P paradigm has been adopted in various countries worldwide [14–17], a 
number of challenges have arisen, hindering its penetrance into mainstream clinical practice. 
The real-world success of the CHR-P paradigm rests on three core components: an efficient 
detection of at risk cases, an accurate prediction of their outcomes and effective preventative 
treatments to alter the course of these outcomes (Figure 1).  
                                                      Enter Figure 1 about here 
 
There are currently barriers to the implementation of each component. Firstly, well-
established CHR-P services [17] detect as low as 5% of first episode psychosis (FEP) patients 
before illness onset [18]. Even within national youth mental health services, the proportion of 
FEP cases detected at their CHR-P stage is only 12% [19]. Secondly, although the prognostic 
performance of the current CHR-P psychometric tools is excellent [20], it is highly dependent 
on the way CHR-P individuals are recruited [21]. Furthermore, prognostic outcomes in this 
population are mostly based on group-level predictions and it is not yet possible to forecast 
the onset of psychosis at the individual-subject level [22]. This is a substantial limitation 
given that the CHR-P group is highly heterogenous and includes different subpopulations 
with differing outcomes [7]. Thirdly, no specific preventive treatment appears to be more 
effective than others in preventing onset of psychosis [23], treating attenuated positive 
symptoms [24,25], treating attenuated negative symptoms [26], treating depressive symptoms 
[27], reducing distress [28], or improving social functioning [29]. Again, the lack of evidence 
may partially reflect the fact that ‘one size fits all’ approaches for this population do not work 
and that individualised treatments should be offered instead. 
 
e-Mental Health is a new approach that may be uniquely suited to overcome some of these 
barriers. Individuals at CHR-P have a young age range (most criteria are set at 14-35 years) 
and as such tend to be highly engaged with the digital world [30]. Though previous reviews 
have highlighted the emerging potential for e-Mental Health in psychosis [31–34], there is 
currently no overview focusing on the potential and prospects specifically in CHR-P. In this 
current perspective, we provide an overview how e-Mental Health can be applied to the 
detection, prediction and treatment of CHR-P. The studies included in this overview are 
summarised in Table 1. Although this is not a systematic review and there is no assumption 
that the literature surveyed is comprehensive, we provide our search strategy and inclusion 
criteria as supplementary material. 
 
e-DETECTION 
Detecting individuals at risk prior to the onset of psychosis has been a key research priority 
over the past two decades since the PACE study first developed the concept of the CHR-P 
[16]. Typical inclusion in the CHR-P group is based on attenuated psychotic symptoms, brief 
episodes of psychosis, or functional deterioration in those with genetic vulnerability for 
psychosis [35,36]. A distinct approach to the identification of CHR-P individuals is the basic 
symptom (BS) concept proposed by Huber and colleagues [37]. BS involve self-experienced 
perceptual and cognitive anomalies that are thought to represent the earliest manifestation of 
psychosis risk [38]. More recent studies have shown that the combined presence of both BS 
and CHR-P criteria increases the predictive power significantly [39]. However, it should also 
be noted that CHR-P participants who do not make transition to psychosis are characterized 
by extensive psychiatric comorbidity and reduced occupational and social functioning [40]. 
Accordingly, these two domains are also potentially important for targets for e-mental health 
applications, both in terms of prediction as well as preventive treatments.   
 
Recruitment strategies have a significant impact on subsequent transition rates of CHR-P 
cohorts; with self-referrals, assertive community outreach and population screening 
associated with lower rates of transition to psychosis [41]. Despite the expansion of CHR-P 
services, only a small proportion of FEP patients are detected [42]. It is thus a key priority for 
CHR-P to improve detection of individuals prior to the FEP while not diluting the sample’s 
baseline risk of psychosis. As the majority of FEP patients actively seek information 
regarding mental health issues online as their symptoms first develop [43], early 
identification of CHR-P individuals may be possible through digital detection strategies. 
These could include online-screening as well as utilization of social media information. 
Recent evidence, for example, suggests that references to sadness, loneliness, hostility, 
rumination, and increased self-reference on Facebook predict later onset of depression [44]. 
A similar approach may be useful in CHR-P as the development of psychosis is characterised 
by linguistic anomalies that can be detect by automated speech analysis [45,46].    
 
Online screening has the potential to reach a greater number of individuals, compared with 
traditional routes of referral to CHR-P services. McDonald et al. [47] utilised a website for 
detection CHR-P in the community. Potential participants were invited via email, flyers and 
posters to a website [48] and then asked to complete the 16-item version of the prodromal 
questionnaire (PQ-16) and 9-item questionnaire of perceptual and cognitive aberrations 
(PCA) for BS (Figure 2). This allowed screening of a large number of individuals (n=2296), 
1202 (52.3%) of whom met PQ-16 cut-off criteria and 1691 (73.6%) of whom met PCA cut-
off criteria. Of the 324 meeting screening cut-off criteria who then attended a clinic 
interview, 101 (31.2%) met clinical CHR-P criteria. Importantly, a subset of eight individuals  
(2.5%) also met criteria for FEP.  Receiver Operating Characteristic (ROC) curve analysis 
revealed good to moderate sensitivity and specificity for predicting CHR-P status, based on 
the online results [47]. A machine-learning approach that selected all 25 items from both the 
PQ-16 and the PCA in addition to demographical variables lead to an improved of specificity 
of 57% while only marginally affecting sensitivity (81%), compared with the original online 
screening tool.  
 
                                                     Enter Figure 2 about here 
 This study suggests that online screening of a community samples for emerging psychosis is 
possible, potentially identifying a large number of people meeting CHR-P criteria. However, 
it is currently unclear how many of these participants meeting CHR-P criteria will actually 
develop psychosis. Accordingly, two-year transition rates are needed to validate whether the 
sample detected are truly ‘at risk’ of developing a psychotic disorder or whether they are 
false positives. A similar approach to McDonald et al. [47] has been implemented using the 
32-item, self-screen prodrome self-screen questionnaire [49]. Though, again, long term 
transition rates are not known. Furthermore, the validity of self-screening questionnaires, 
particularly when conducted in non-clinical populations has been questioned [50], due to 
poor prognostic performance in predicting subsequent psychosis. 
 
More targeted screening of populations accessing secondary mental health services that use 
Electronic Health Records is also possible through online screening. Our group developed a 
psychosis risk calculator for patients already accessing secondary mental health services [18]. 
This tool uses routine clinical data, including International Classification of Diseases-10 
(ICD-10) spectra diagnoses to predict future risk of developing a psychotic disorder and has 
been externally validated twice in different NHS Trusts [51] showing an acceptable 
prognostic performance (Harrell’s C of 0.73). Patients who have accessed secondary mental 
health services have a 5-fold increased risk compared with the general population [18], 
suggesting this may be an efficient way of detecting new cases of psychosis while not 
diluting the level of risk in the sample. As it utilises routine clinical data, the calculator could 
be used to automatically screen electronic health records for those at increased risk of future 
psychosis. However, it does rely on the assessment of health professionals to provide ICD-10 
diagnoses, therefore it cannot be used universally for self-screening. The calculator is one of 
the few e-Health tools in the CHR-P population that is being implemented into clinical 
routine practice [52].    
 
The North American Prodrome Longitudinal Study has  produced an online risk calculator 
for CHR-P individuals meeting CHR-P criteria [53]. It showed an overall accuracy of 72% in 
predicting psychosis when validated in an independent external data set [54]. However, it 
requires input in the form of a structured interview to confirm CHR-P status and 
neuropsychological testing, limiting its applicability to wider clinical populations.  
 
e-Mental Health offer the opportunity for efficient, scalable screening of those at risk of 
psychosis across populations that are currently not reached by conventional recruitment, 
potentially allowing better detection of individuals prior to their FEP. Preliminary evidence 
suggests that it is indeed feasible. The next step is determining whether these tools can be 
implemented in practice to identify individuals at increased risk of psychosis, while not 
diluting the overall risk of the sample with false positives. 
 
e-PROGNOSIS 
The risk of transition to psychosis from CHR-P is maximal within the first two years [55]. 
This period is therefore crucial time for predicting onset of psychosis. Traditionally, this has 
been achieved through regular clinical monitoring from CHR-P services to assess for 
transition to psychosis but advances in smartphone technology offers the opportunity for a far 
greater temporal resolution in monitoring changes in mental state which may occur on a daily 
or even momentary basis.  
 
Experience Sampling Method (ESM) utilises smartphones to measure self-rated changes in 
mental state on a daily basis [56]. It has excellent ecological validity and allows close 
monitoring of mental state, particularly in regard to predictors of transition to psychosis. 
ESM techniques in CHR-P were initially rudimentary, requiring participants to fill out 
responses on a paper diary when prompted by a wristwatch alarm [57,58]. Palmier et al. [59] 
demonstrated that it is feasible to monitor symptoms through a smartphone app in a small 
sample (n=12) of CHR-P individuals, paving the way for further cross-sectional ESM studies. 
Klippel et al. [60] showed in 46 CHR-P individuals that momentary stress increased 
psychotic experiences via affective disturbance, using the PsyMate device. Reininghaus et al. 
[61] used ESM to link threat perception to psychotic experiences in 44 CHR-P individuals 
and in another study [62] to show an association with sensitivity to outsider status and 
aberrantly salient experiences with psychotic experiences. van der Steen et al. [63] used ESM 
to demonstrate an association between affective and psychotic experiences in response to 
stress in CHR-P individuals, showing an association between stress and psychotic 
experiences. ESM has shown potential utility in monitoring fine-grained changes in 
psychopathology during the development of psychosis, however longitudinal studies are 
needed to determine its significance for predicting the onset of psychosis. To date, one 
longitudinal study has been registered [64]. Specifically, Booij et al. plan to predict outcome 
in various stages of psychosis using smartphone diary measures of symptoms, stress, 
emotions and functioning. 
 
Digital phenotyping, also known as personal sensing, is a novel investigational technique 
whereby passive measures of smartphone activity are recorded in real-time [65] which has 
been postulated to provide a ‘digital phenotype’ of psychiatric disorders [66]. These measures 
may include the participant’s interaction with their phone (for example, call logs, number of 
messages, keyboard use) as well as measures of their activity and movement (for example, 
through accelerometers or GPS tracking). Passive data provides a continuous readout every 
day and requires no active role by the participant, thus providing significant advantages over 
traditional, episodic cross-sectional data. Passive data is also potentially more ecologically 
valid than symptom-ratings elicited by standard questionnaires or interviews, and there is 
reduced risk of subject attrition.  
 
However, the use of passive smartphone measures warrants some important ethical 
considerations [65]. As with any investigation, informed consent, data security and 
anonymisation are crucial. Additionally, in those with psychotic disorders care must be taken 
not to exacerbate paranoia when utilising participants’ personal devices. It therefore may be 
particularly suited to CHR-P individuals, who retain insight, particularly for the prediction of 
psychosis onset. Unlike ESM, it does not require continual user input and may therefore be 
less burdensome to participants. A pilot study [67] suggests digital phenotyping could predict 
relapse in schizophrenia based on anomalies in patient behaviour; further studies in CHR-P 
populations are underway, for example, using the MindStrong app [68].  
 
ESM and digital phonotypes have complementary strengths. ESM provides explicit 
information about a patient’s state of mind, and as such is key to understanding their 
motivations and behaviours; whereas digital phenotyping has the important advantage of 
placing minimal burden on the patient apart from keeping their mobile phone charged, and as 
such is ideal for clinical translation. Initial studies suggest that it might be possible to use 
‘passive’ data generated via digital phenotyping as a proxy for ‘active’ data collected via 
ESM [69]; in the context of CHR-P, this could enable the background monitoring of risk of 
transition to psychosis with minimal interference on the day-to-day life of patients. 
 In addition to informing diagnosis, prognosis and treatment, e-tools could be used to gain 
greater understanding of the mechanisms that underlie transition to psychosis. For example, 
our research team are currently using the Urban Mind app [70] to investigate the impact of 
the surrounding social and physical environment on risk of transition to psychosis in 
individuals at CHR-P (see Figure 2 for user interface). 
 
Enter Figure 3 about here 
 
The above studies suggest that e-Mental Health has potential value in identifying risk factors 
for subsequent transition to psychosis and predicting the onset of psychosis. In addition, these 
approaches may also be applied towards prognosis for outcomes other than transition to 
psychosis, such as functional outcomes and development of non-psychotic disorders. ESM 
and digital phenotyping are two appealing methodologies with great promise, and are ideally 
suited to longitudinal designs to examine the development of clinical trajectories in CHR-P 
populations. 
 
e-TREATMENT 
One criticism of CHR construct is that there is no treatment conclusively shown to prevent 
the onset of psychosis [71]. However, there are several promising therapeutic strategies 
currently under investigation that could significantly reduce psychosis-risk as well as address 
important additional areas of impairment, in particular cognitive deficits and social and 
occupational functioning.   
 
Since individuals at CHR-P do not have a mental disorder as such, any treatment has to be 
well tolerated and acceptable. Moreover, by definition these individuals retain a degree of 
insight into their symptoms [72], offering a significant therapeutic window of opportunity 
prior to the onset of psychosis. Guidelines currently suggest psychological therapy and 
recommend not treating with antipsychotic medication [73]. As various psychological 
therapies can be delivered online, e-Mental health has the potential to enhance access to 
treatments and reduce costs.  A systematic review and meta-analysis suggested that guided 
online CBT for various psychiatric disorders had equivalent effect sizes compared with face-
to-face interventions [74], highlighting the potential utility of administering CBT through 
digital modalities. Other psychological interventions such as mindfulness, which has shown 
some efficacy for psychosis [75], may also be effective when provided online [76]. Alvarez-
Jiminez et al. [77] conducted a novel strengths and mindfulness-based online social therapy 
for individuals at CHR-P. Participants found the intervention acceptable and showed an 
improvement in social functioning and subjective wellbeing, warranting further study. 
 
Digital interventions showing promise in established psychosis, relevant to CHR-P, include 
avatar therapy [78], online CBT skills programme for hallucinations [79], smartphone apps 
delivering therapeutic interventions [80–82] and online peer-to-to peer support networks 
which are reported to increase feelings of social connectedness [83]. Indeed, Rice et al. [84] 
have developed an e-Mental Health service, providing clinician-delivered web chat 
counselling, a moderated peer-to-peer social network, user directed online therapy. This 
‘enhanced moderated online social therapy’ is seeded in eheadspace, part of headspace, a 
flagship Australian youth mental health programme with an integrated early intervention in 
psychosis component [85]. 
 
An important aspect of the clinical presentation of CHR-P are cognitive deficits across a 
range of domains that are associated with transition to psychosis [86,87]. One way of 
targeting cognitive deficits in CHR-participants could be cognitive remediation (CR)-based 
treatments [88] that can be administered via  computerized training procedures [89]. These 
approaches improve neural circuits underlying cognitive deficits with significant impact on 
social functioning [90], especially if administered in the early stages of schizophrenia [91]. 
There is emerging evidence that CR treatments may be effective in targeting cognitive 
dysfunctions in CHR-participants. Loewy et al. [92] examined the effects of CR administered 
through laptop and home computers on verbal learning and memory. Cognitive remediation 
significantly improved verbal memory (effect size = 0.61) as well as positive symptoms. 
Hooker et al. present a pilot, uncontrolled study of cognitive training delivered online for 
CHR-P [93], showing this intervention is feasible and appear to provide improvements in the 
global cognition in response to training. 
 
Digital interventions could also be extended to address functional impairments in CHR-P 
individuals. In a recent study, Schlosser et al. [82] examined a mobile-based digital health 
intervention designed to improve motivation and quality of life in young people with 
schizophrenia. Compared to the control group, the active treatment arm demonstrated  
significant improvements in levels of depression, defeatist beliefs, self-efficacy, and a trend 
for improved negative symptoms. These improvements were maintained three months after 
the end of trial. Accordingly, these data suggest that mobile-based intervention could be 
useful for addressing important domains of functioning in CHR-P populations. 
 
Virtual reality (VR) is an emerging tool for the treatment of a wide range of mental disorders 
that involves interactive computer-generated worlds in which therapeutic strategies can be 
implemented  and tested [94]. In established schizophrenia, VR-approaches have shown 
preliminary efficacy in targeting positive symptoms, such as delusions [95] and 
hallucinations [96], as well as increasing social participation [97]. VR has also shows 
potential as a treatment adjunct in psychosis, in modalities such as cognitive remediation, and 
social skills training [98], showing preliminary promising results. 
 
Following successful pilot research demonstrating the safety of VR in the CHR-P population 
[99], this technique has been used to investigate the effect of various simulated social 
environments on psychopathology. A simulation of the London underground transport system 
has been used to investigate paranoid ideation [100,101] and perceived ethnic discrimination 
[102]. While café [103] and bar simulations [104] have been used to investigate the effect of 
social stress on interpersonal distance and paranoid ideation, respectively. These studies show 
the possibilities of using VR to study psychopathology in a simulated environment. 
Arguably, it may be better suited as a treatment modality in CHR-P, compared with more 
established stages of psychosis. 
 
Table 1. Summary of Included Studies of e-Mental Health in CHR-P 
Study Summary Results 
e-Detection 
McDonald 
et al. 2018 
[47]   
Web-based community screening 
for CHR-P 
Good to moderate sensitivity and 
specificity for predicting CHR status 
based on online screening 
Fusar-Poli 
et al. 2017 
[18] 
Risk calculator based on routine 
clinical data of patients accessing 
secondary health services 
Acceptable predictive performance, 
Harrell's C 0.80 (0.79-0.82) 
Fusar-Poli 
et al. 2018 
[51] 
External validation of the above 
study in a second NHS trust 
Acceptable predictive performance, 
Harrell’s C of 0.73 
Fusar-Poli 
et al. 2019 
[52] 
Protocol for implementation study 
of the above into routine clinical 
care 
N/A 
Cannon et 
al. 2016 [53] 
Risk calculator based on specialised 
clinical assessment 
Acceptable predictive performance, 
Harrell's C 0.71 
Carrión et 
al. 2016 [54] 
External valiation of the above 
study in a second cohort 
Good discrimination Area Under the 
Curve 0.790 (0.644–0.937).    
e-Prognosis 
Palmier-
Claus et al. 
2012 [59] 
Feasibility of smartphone self-
report of symptoms using the 
ClinTouch app 
36/42 participants (82%) compliant 
with the smartphone measures 
Klippel et 
al. 2017 [60] 
ESM study of stress and psychotic 
symptoms, using the PsyMate 
device 
Effects of stress on psychotic 
experiences were mediated through 
affective disturbance 
Reininghaus 
et al. 2016 
[61] 
ESM study of threat perception and 
psychotic experiences using 
PsyMate device 
Outsider status  and threat anticipation 
were associated with more intensite 
psychotic experiences in those who 
experienced sexual abuse, compared 
with those exposed to low levels of 
sexual abuse. 
Reininghaus 
et al. 2016 
[62] 
ESM study of sensitivity to outsider 
status, salient experiences and 
psychotic experiences using the 
PsyMate device 
Elevated stress sensitivity, aberrant 
salience and enhanced threat 
anticipation associated increased 
intensity of psychotic experiences. 
van der 
Steen et al. 
2017 [63] 
ESM study of affective and 
psychotic experience in response to 
stress using a digital wrist watch to 
instruct participants to enter written 
self-report and random timepoints 
Greater associations between negative 
affect and stress compared with 
psychotic patients (p = 0.008) and 
controls (p < 0.001). 
Booij et al. 
2018 [64] 
Study protocol of longitudinal ESM 
smartphone study 
N/A 
   
e-Treatment 
Alvarez-
Jimenez et 
al. 2018 [77] 
Pilot study of online social therapy 
intervention, MOMENTUM 
70% actively engaged during the study. 
All reported positive experiences, 
considered it safe and would 
recommend it to others. 93% reported 
it to be helpful. Large improvements in 
social functioning (d= 1.83, p<0.001) 
and subjective wellbeing (d=0.75, p = 
0.03). 
Rice at al. 
2018 [84] 
Study protocol for Enhanced 
Moderated Online Social Therapy 
(MOST) 
N/A 
Hooker et 
al. 2014 [93] 
Pilot uncontrolled study of online 
cognitive training 
Significant improvements in 
processing speed p=0.01, d=0.63, and 
non-significant improvements in visual 
learning and memory p=0.06, d=.54 
and global cognition p=0.06, d=0.45. 
Valmaggia 
et al. 2007 
[99] 
Study of the feasibility and safety 
of VR environments 
No adverse events, no increase in mean 
anxiety score p=0.287. 
Valmaggia 
et al. 2015 
[101] 
VR study assessing social defeat 
and paranoid appraisals in a 
simulation of the London 
underground 
More paranoid appraisals of VR 
simulations compared with controls 
p<0.001 
Valmaggia 
et al. 2015 
[100] 
VR study assessing childhood 
bullying and paranoid ideation in a 
simulation of the London 
underground 
More paranoid ideation during VR 
simulation compared with controls 
χ2(1)=21.06, p<0.001. 
Shaikh et al. 
2016 [102] 
VR study assessing ethnic 
discrimination and persecutory 
paranoia in a simulation of the 
London underground 
Higher levels of perceived ethnic 
discrimination correlated with greater 
paranoid persecutory ideation in VR 
environment r=0.25, p=0.009. 
Geraets et 
al. 2018 
[103] 
VR study assessing interpersonal 
distance regulation in a simulated 
café  
Interpersonal distance increased when 
social stressors were present in the 
environment F=3.02, p = 0.02 
Veling et al. 
2016 [104] 
VR study assessing paranoia in a 
simulated bar environment 
Increased paranoia compared with 
controls, regression coefficient 3.80 
(95%CI 0.24–7.37) p=0.037 
 
 
Conclusion 
Digital technologies are at present under-used as a research or clinical tool for CHR-P and 
may be ideally placed to address the current challenges of the field. These include detecting 
those at risk of psychosis outside specialised CHR-P clinics, monitoring to predict future 
development of psychosis, identifying digital biomarkers for psychosis and other clinical 
outcomes, as well as delivering novel treatment modalities. Furthermore, individuals at CHR-
P, by definition young and help seeking, are ideally suited to digital interventions. However, 
longitudinal studies of digital technologies are required to assess which measures are useful 
for predicting risk of psychosis in individuals identified by online screening. Future research 
is required to rigorously test whether digital interventions have a place in the detection or 
management in people at CHR-P. In addition, we need greater understanding of the 
relationship between the different types of measures (e.g. ‘active’ and ‘passive’ data collected 
via ESM and digital phenotyping respectively) in order to develop and validate e-tools that 
provide maximal information while minimizing burden on the patient. 
 Acknowledgements 
This study was supported by the King’s College London Confidence in Concept award from 
the Medical Research Council (MRC) (MC_PC_16048) to PFP. This study also represents 
independent research part funded by the National Institute for Health Research (NIHR) 
Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and 
King’s College London. The views expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health and Social Care. The funders had 
no influence on the design, collection, analysis and interpretation of the data, writing of the 
report and decision to submit this article for publication. 
 
Conflicts of Interest 
None.
Figure Captions.  
 
 
Figure 1. Core clinical and research components for effective prevention of psychosis, from 
Fusar-Poli et al. 2019. Illustration of medication is indicative only and does not represent 
antipsychotics. 
 
Figure 2. YouR study website screening questionnaire 
 
Figure 3. Urban Mind app, example user interfaces 
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